oxLDL

By Targets:	Apoptosis (3) Biochemical Assay Reagents (1) Histone Methyltransferase (1) Keap1-Nrf2 (3) LDLR (1) LOX-1 (1) NF-κB (1) Phospholipase (1) Reactive Oxygen Species (1) Sirtuin (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (6) Inflammation/Immunology (2) Metabolic Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-23999

BI-0115	LOX-1	Cardiovascular Disease
BI-0115 is a selective inhibitor of LOX-1 (IC₅₀=5.4 µM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain .

HY-126726

KOdiA-PC	Biochemical Assay Reagents	Others
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-156081

Nrf2 activator-9	Keap1-Nrf2 Apoptosis	Metabolic Disease
Nrf2 activator-9 (compound D-36) is an Nrf2 activator that inhibits oxidized low-density lipoprotein (oxLDL) and high glucose (HG)-induced apoptosis in HUVEC cells. Nrf2 activator-9 inhibits oxLDL and HG-induced vascular endothelial cell (VEC) injury and can effectively prevent and treat atherosclerosis .

HY-143243

Antioxidant agent-5	Apoptosis NF-κB Keap1-Nrf2 Reactive Oxygen Species	Cardiovascular Disease
Antioxidant agent-5 (compound D-6) is a potent antioxidant agent. Antioxidant agent-5 can inhibit oxLDL (oxidized low-density lipoprotein)-induced apoptosis and the expression of ICAM-1 and VCAM-1 in VECs. Antioxidant agent-5 suppresses oxLDL-induced increase of ROS level and nuclear translocation of NF-κB. Antioxidant agent-5 protects against oxLDL-induced endothelial injury by activating Nrf2/HO-1 anti-oxidation pathway .

HY-125554

KDdiA-PC

Others Cardiovascular Disease

KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL) .

KDdiA-PC	Others	Cardiovascular Disease
KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL) .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-130576

POVPC	Apoptosis	Cardiovascular Disease
POVPC is an oxidized phospholipid can be found in in oxidatively modified low density lipoprotein (oxLDL). POVPC inhibits VSMC growth in high serum condition. POVPC induces apoptosis in low serum condition .

HY-149120

ASM-IN-1	Phospholipase	Cardiovascular Disease Inflammation/Immunology
ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC₅₀ value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .

HY-122936

Tanshindiol C	Histone Methyltransferase Keap1-Nrf2 Sirtuin	Cardiovascular Disease Cancer
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research .

Cat. No.	Product Name	Type

HY-126726

KOdiA-PC	Biochemical Assay Reagents
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

KOdiA-PC

Biochemical Assay Reagents

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

Cat. No.	Product Name	Target	Research Area

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-122936

Tanshindiol C	Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants	Histone Methyltransferase Keap1-Nrf2 Sirtuin
Tanshindiol C is a S-adenosylmethionine-competitive EZH2 (Histone Methyltransferase) inhibitor with an IC₅₀ of 0.55 μM for inhibiting the methyltransferase activity. Tanshindiol C is also an activator of both Nrf2 and Sirtuin 1 (Sirt1) in macrophages. Tanshindiol C possesses anti-cancer activity, and can be used for atherosclerosis research .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P71180

	OLR1 Protein, Human (HEK293, His) Oxidized Low-Density Lipoprotein Receptor 1; Ox-LDL Receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL Receptor 1; LOX-1; Lectin-Like oxLDL Receptor 1; hLOX-1; Lectin-Type Oxidized LDL Receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	OLR1 Protein, a receptor on vascular endothelial cells, plays a key role in recognizing, internalizing, and degrading oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces vascular endothelial cell activation, leading to pro-inflammatory responses, oxidative conditions, and apoptosis. OLR1's association with oxLDL activates NF-kappa-B, contributing to pro-atherogenic responses such as reduced nitric oxide release, monocyte adhesion, and apoptosis. Beyond oxLDL, it serves as a receptor for HSP70, participating in cell-mediated antigen cross-presentation and functioning as a leukocyte-adhesion molecule in inflammation. Additionally, OLR1 recognizes AGE products, activated platelets, monocytes, apoptotic cells, and bacteria. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293, with C-6*His labeled tag. The total length of OLR1 Protein, Human (HEK293, His) is 213 a.a., with molecular weight of 30-35 kDa.

HY-P77986

	LOX-1/OLR1 Protein, Mouse (HEK293, His) Ox-LDL receptor 1; LOX-1; CLEC8A; LOX1; OLR1; LOXIN; SR-E1; SCARE1; SLOX1	Mouse	HEK293
	The LOX-1/OLR1 protein is a receptor on vascular endothelial cells that promotes the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). This process is indicative of atherosclerosis and triggers endothelial cell activation, pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Mouse (HEK293, His) is 304 a.a., with molecular weight of 55-63 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Application	Reactivity

HY-P81166

ox-LDL Antibody ox-LDL: LDL (Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; Low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein. 氧化型低密度脂蛋白；	ELISA; IHC-P; IHC-F; Flow-Cyt; IF	Human,
ox-LDL Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-ox-LDL polyclonal antibody. ox-LDL Antibody can be used for: ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, background without labeling.

HY-P81172

LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: Oxidized low-density lipoprotein receptor 1, soluble form A; Oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB; ELISA; IHC-P; IHC-F; IF	Human, Rat, Rabbit(predicted: Mouse, Cow)
LOX 1 Antibody is an unconjugated, approximately 31/50 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, rat, rabbit, and predicted: mouse, cow background without labeling.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

oxLDL

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products